


# **Example of joint symposium organized by UEG and EMA**

Presentation by

**Prof. M. DELVAUX**University Hospital of Strasbourg
Public Affairs Committee UEG

## What is UEG?



© UEG. 2012

### Interest focus of our members

Academic experts

Researchers, university physicians

Private practice physicians

Trainees, fellows

Drug efficacy

Drug Safety

New upcoming treatments

Clinical trials

Guidelines

Guidelines

Guidelines

3 © UEG. 2012



## **UEGW: 14,000 Attendees**

About UEG Week Education Journal EU Affairs

search Awards & Grants Press News Contact Us myUEG

Activities Fighting CRC | Patient Engage

#### **Latest Activities**



#### Obesity: climbing higher on the EU agenda European Obesity Day will highlight the need for action

The need for Obesity to be officially recognised as a disease in Europe was the focus of a high-level reundtable discussion attended by UES in Brussels in January.

#### About UEG EU Affairs

30% of the European population is affected by a GI disease at least once during their lifetime. Even so, gastroenterology is still not a priority on the health agenda.

#### Our Vision

To listen to and learn from public opinion and to increase knowledge and stimulate activity in the area of digestive diseases, among the public and politicians.

#### Contact

UEG EU Affairs Aleksandra Kaczmarek

UES Brussels Office Rue Defarqz 52 1050 Brussels Belgium

T+32 2536 86 68

publicaffairs@ueg.eu



#### The Scientific Panel for Health - "Better research for better health"

UEG President Michael Manns addresses how health research challenges and opportunities can be tackled at the EU level. Find out more

#### UEG partners with other European NGOs in the fight

against pancreatic cancer
Pancreatic cancer is one of the most lethal digestive disorders, with a Panchaltic Cancer is one of the most formal digestion interests, with a long-term survival rate of less than 5%. Aft he same time, if a predicted to become the second most lathal cancer in the EU by 2030, But doughle its lothality and the rising burden, pancreatic cancer is a neglected disease, as policy-makers give little political attention and funding for innovative research.



#### Gastro and liver disease

Dealer by Fet Branding

Development by Melchgerour Röckler

Our map summarises gastro and liver diseases based on an assessment of riignstive health across Europe. Find out more



#### Joint working initiatives

UEG is actively orgaging with a range of patient organisations to share best practice and increase awareness.

Community

Facebeas

L'exact t



#### Survey of digestive diseases

Changing trends in GI diseases and healthcare provision in Europe are now summarised in a handy booklet.

Browse the White Book epoper

(C USG 2005

All inights reserved. Use of this we have not stituted acceptance of the Boar Agreement, the Seneral Terms and Canalities and the Data Potraction Statements.

About this after inprint Privacy policy. Sector & possitions

Contact

Sinhed European Gastros instology (USS) Amon of Surgous Sastronterslogy Wickenburgs, L. 1986 Viennia, Austria. T-63 1987 WS F + Ag 1907 16 50 18 office@anguio

Contact USE Week Attendance USG Week Bifficial Registration Partner T+45 75880 48

Largue et. registration@mendiat-cangress.com

## Symposium UEG - EMA October 2013, in Berlin

## Drug issues in Gastroenterology: A European perspective

Chairs: I. Moulon, JF Colombel

Unmet needs for drug development in

the field of digestive diseases

Medicines evaluation in Europe: J. Musaus

Current status and future plans

Pharmacovigilance: The point of view of healthcare C. Zeuzem

**Professionals** 

Monitoring drugs after licensing: The patient's perspective

Pharmacovigilance in Europe: Where are we and how

can we improve?

P. Michetti

I. Moulon

J. Tack

## Symposium UEG - EMA October 2016, in Vienna

# Critical isues in drug development for Digestive diseases: A joint UEG – EMA symposium

Chairs: J. Atherton (UEG), J. Musaus (EMA)

The introduction of biosimilars in IBD and Oncology

The Clinician perpsective IBD

The Clinician perspective Oncolgy

The responses of EMA

S. Danese

E. Van Cutsem

P. Kurki

### Drug Development in paediatric patients

- Are outcomes of adult studies applicable to paediatric patients? G. Veereman
- The paediatric committee in EMA

J. Taminiau

### Clinical studies in elderly patients

- The point of view of primary care physicians
- Addressing special groups of pateints: The EMA perspective

R. Jones

I. Moulon





If you are interested in finding out more about UEG visit www.ueg.eu

Like us on Facebook at www.facebook.com/ueg
Tweet us on @ueg

Presentation by

Prof. M. DELVAUX
University Hospital of Strasbourg
Public Affairs Committee UEG